Search Result

Results for "

chronic anemia

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (1) Biochemical Assay Reagents (4) Caspase (1) Environmental Pollutants (3) Ferroportin (2) Hepcidin (1) HIF/HIF Prolyl-Hydroxylase (14) Isotope-Labeled Compounds (1) Reactive Oxygen Species (ROS) (1) Reference Standards (3) TGF-β Receptor (1)
By Research Areas:	Cancer (3) Cardiovascular Disease (14) Inflammation/Immunology (3) Metabolic Disease (5)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-17608

Daprodustat Maximum Cited Publications 20 Publications Verification GSK1278863	HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease
Daprodustat (GSK1278863) is an orally active hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor being developed for the treatment of anemia associated with chronic kidney disease.

HY-N1428C

Ferric citrate 5 Publications Verification Iron(III) citrate; Zerenex	Reactive Oxygen Species (ROS) Antibiotic	Metabolic Disease
Ferric citrate (Iron(III) citrate), an orally active iron supplement, is an efficacious phosphate binder. Ferric citratee can be used for iron deficiency anemia and chronic kidney disease (CKD) research .

HY-Y1103

Iron(II) sulfate heptahydrate, 99% 1 Publications Verification Ferrous sulfate heptahydrate, 99%	Environmental Pollutants Biochemical Assay Reagents	Cardiovascular Disease Cancer
Iron(II) sulfate heptahydrate, 99% (Ferrous sulfate heptahydrate, 99%) is an orally active iron salt. Iron(II) sulfate heptahydrate, 99% replaces iron found in hemoglobin and myoglobin, allowing for the transportation of oxygen via hemoglobin. Iron(II) sulfate heptahydrate, 99% is mainly used for the prevention of iron-deficiency anemia. Iron(II) sulfate heptahydrate, 99% also has anti-tumor effects on chronic myeloid leukemia and breast cancer .

HY-12654

Molidustat 5+ Cited Publications BAY 85-3934	HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease
Molidustat (BAY 85-3934) is an orally active inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) with IC₅₀ values of 480 nM, 280 nM, and 450 nM for PHD1, PHD2, and PHD3, respectively. Molidustat can elevate the levels of circulating erythropoietin (EPO) to near-normal physiological ranges. Molidustat can be utilized in the research of renal anemia .

HY-101277

Vadadustat 5+ Cited Publications PG-1016548; AKB-6548	HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease
Vadadustat (PG-1016548) is a titratable, oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor . Vadadustat is an erythropoiesis-stimulating agent and has the potential for anemia treatment in chronic kidney disease in vivo .

HY-Y1103A

Iron(II) sulfate heptahydrate, for cell culture, 99% 1 Publications Verification Ferrous sulfate heptahydrate, for cell culture, 99%	Environmental Pollutants Biochemical Assay Reagents	Cardiovascular Disease Cancer
Iron(II) sulfate heptahydrate, for cell culture, 99% (Ferrous sulfate heptahydrate, for cell culture, 99%) is an orally active iron salt. Iron(II) sulfate heptahydrate, for cell culture, 99% replaces iron found in hemoglobin and myoglobin, allowing for the transportation of oxygen via hemoglobin. Iron(II) sulfate heptahydrate, for cell culture, 99% is mainly used for the prevention of iron-deficiency anemia. Iron(II) sulfate heptahydrate, for cell culture, 99% also has anti-tumor effects on chronic myeloid leukemia and breast cancer .

HY-47030

Ferric citrate hydrate	Environmental Pollutants Biochemical Assay Reagents	Metabolic Disease
Ferric citrate hydrate, an orally active iron supplement, is an efficacious phosphate binder. Ferric citrate hydrate can be used for iron deficiency anemia and chronic kidney disease (CKD) research .

HY-P3761

Ac-Tyr-Val-Lys-Asp-aldehyde	Caspase	Inflammation/Immunology
Ac-Tyr-Val-Lys-Asp-aldehyde is a reversible caspase-1 inhibitor. Ac-Tyr-Val-Lys-Asp-aldehyde increases GATA1 levels by inhibiting caspase-1 and promotes erythroid differentiation. can be used for disease research including anemia-associated to chronic diseases, chemotherapy-induced anemia and Diamond-Blackfan anemia .

HY-17608R

Daprodustat (Standard) GSK1278863 (Standard)	Reference Standards HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease
Daprodustat (Standard) is the analytical standard of Daprodustat. This product is intended for research and analytical applications. Daprodustat (GSK1278863) is an orally active hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor being developed for the treatment of anemia associated with chronic kidney disease.

HY-101277S1

Vadadustat-13C6 PG-1016548-¹³C₆; AKB-6548-¹³C₆	Isotope-Labeled Compounds HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease
Vadadustat- ¹³C₆ (PG-1016548- ¹³C₆) is ¹³C labeled Vadadustat. Vadadustat (PG-1016548) is a titratable, oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor . Vadadustat is an erythropoiesis-stimulating agent and has the potential for anemia treatment in chronic kidney disease in vivo .

HY-125288

DS42450411	Ferroportin	Metabolic Disease
DS42450411 is an orally active hepcidin production inhibitor with an IC₅₀ of 32 nM. DS42450411 in an acute inflammatory mouse model induced by IL-6, DS42450411 significantly reduces serum hepcidin levels. DS42450411 can be used for studying iron homeostasis .

HY-W747868

Molidustat sodium	HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease
Molidustat sodium is an orally active inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) with IC₅₀ values of 480 nM, 280 nM, and 450 nM for PHD1, PHD2, and PHD3, respectively. Molidustat sodium can elevate the levels of circulating erythropoietin (EPO) to near-normal physiological ranges. Molidustat sodium can be utilized in the research of renal anemia .

HY-170915

DDO-3055	HIF/HIF Prolyl-Hydroxylase	Others
DDO-3055 is an orally active PHD2 inhibitor that can be used in the research of anemia associated with chronic kidney disease .

HY-163148

PHD-IN-3	HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease
PHD-IN-3 (Compound 15) is an orally active PHD inhibitor. PHD-IN-3 can be used in the study of anemia associated with chronic kidney disease .

HY-124133

JNJ-42905343	HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease
JNJ-42905343 is an orally active and highly selective prolyl hydroxylase (PHD1/2/3) inhibitor with pK_I values of 8.07, 7.48 and 7.27 for PHD1, PHD2 and PHD3, respectively. JNJ-42905343 is promising for research of functional iron deficiency (FID) and anemia of chronic disease (ACD) .

HY-170917

PHD2-IN-4	HIF/HIF Prolyl-Hydroxylase
PHD2-IN-4 (compound 1) is a PHD2 inhibitor. PHD2-IN-4 inhibits PHD2 with an IC₅₀ of 4 nM. PHD2-IN-4 is potential for chronic kidney disease research .

HY-170914

JPHM-2-167	HIF/HIF Prolyl-Hydroxylase	Metabolic Disease
JPHM-2-167 (Compound 11) is a selective PHD (prolyl hydroxylase domain enzyme) inhibitor. JPHM-2-167 inhibits PHD2, PHD3 with IC₅₀s of 0.253 μM and 3.95 μM, respectively. JPHM-2-167 can be used for chronic kidney disease .

HY-12654R

Molidustat (Standard) BAY 85-3934 (Standard)	HIF/HIF Prolyl-Hydroxylase Reference Standards	Cardiovascular Disease
Molidustat (Standard) is the analytical standard of Molidustat. This product is intended for research and analytical applications. Molidustat (BAY 85-3934) is an orally active inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) with IC50 values of 480 nM, 280 nM, and 450 nM for PHD1, PHD2, and PHD3, respectively. Molidustat can elevate the levels of circulating erythropoietin (EPO) to near-normal physiological ranges. Molidustat can be utilized in the research of renal anemia .

HY-101277R

Vadadustat (Standard) PG-1016548 (Standard); AKB-6548 (Standard)	HIF/HIF Prolyl-Hydroxylase Reference Standards	Cardiovascular Disease
Vadadustat (Standard) is the analytical standard of Vadadustat (HY-101277). This product is intended for research and analytical applications. Vadadustat (PG-1016548) is a titratable, oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor . Vadadustat is an erythropoiesis-stimulating agent and has the potential for anemia treatment in chronic kidney disease in vivo .

HY-P991881

KY1070	TGF-β Receptor Hepcidin Ferroportin	Cardiovascular Disease
KY1070 is a fully human anti-BMP6 antibody with a K_d of 0.00014 μM against the human BMP6. It exhibits high specificity for BMP6, showing no cross-reactivity with other members of the BMP family, and effectively inhibits BMP6-induced BMP receptor heterodimerization and hepcidin expression. KY1070 modulates Ferroportin expression on erythroid progenitor cells and accelerates erythropoiesis. In rodent anemia models, KY1070 reduces the required dose of erythropoietin (EPO) when used in combination with EPO and enhances the responsiveness of mice with chronic kidney disease (CKD)-associated anemia to EPO treatment. KY1070 is applicable for research on anemia of chronic disease ^{[1] [2]}.

HY-180560

PHD-IN-5	HIF/HIF Prolyl-Hydroxylase	Inflammation/Immunology
PHD-IN-5 (ISM4808) is an orally active PHD inhibitor that can be used for studying anemia in chronic kidney disease .

HY-W581798

Iron(II) sulfate hydrate	Biochemical Assay Reagents	Metabolic Disease Cancer
Iron(II) sulfate hydrate is an iron(II) salt with oral activity, acting as an iron supplier, and is easily oxidized to iron(III) in water. Iron(II) sulfate hydrate induces apoptotic morphological changes in cancer cells, and promotes dose‑dependent iron accumulation in rats. Iron(II) sulfate hydrate can be used in studies of leukemia, breast cancer, iron deficiency, anemia, and restless legs syndrome .

Cat. No.	Product Name	Type

HY-Y1103

Iron(II) sulfate heptahydrate, 99% 1 Publications Verification Ferrous sulfate heptahydrate, 99%	Biochemical Assay Reagents
Iron(II) sulfate heptahydrate, 99% (Ferrous sulfate heptahydrate, 99%) is an orally active iron salt. Iron(II) sulfate heptahydrate, 99% replaces iron found in hemoglobin and myoglobin, allowing for the transportation of oxygen via hemoglobin. Iron(II) sulfate heptahydrate, 99% is mainly used for the prevention of iron-deficiency anemia. Iron(II) sulfate heptahydrate, 99% also has anti-tumor effects on chronic myeloid leukemia and breast cancer .

Iron(II) sulfate heptahydrate, 99%

1 Publications Verification

Ferrous sulfate heptahydrate, 99%

Biochemical Assay Reagents

Iron(II) sulfate heptahydrate, 99% (Ferrous sulfate heptahydrate, 99%) is an orally active iron salt. Iron(II) sulfate heptahydrate, 99% replaces iron found in hemoglobin and myoglobin, allowing for the transportation of oxygen via hemoglobin. Iron(II) sulfate heptahydrate, 99% is mainly used for the prevention of iron-deficiency anemia. Iron(II) sulfate heptahydrate, 99% also has anti-tumor effects on chronic myeloid leukemia and breast cancer .

HY-Y1103A

Iron(II) sulfate heptahydrate, for cell culture, 99% 1 Publications Verification Ferrous sulfate heptahydrate, for cell culture, 99%	Biochemical Assay Reagents
Iron(II) sulfate heptahydrate, for cell culture, 99% (Ferrous sulfate heptahydrate, for cell culture, 99%) is an orally active iron salt. Iron(II) sulfate heptahydrate, for cell culture, 99% replaces iron found in hemoglobin and myoglobin, allowing for the transportation of oxygen via hemoglobin. Iron(II) sulfate heptahydrate, for cell culture, 99% is mainly used for the prevention of iron-deficiency anemia. Iron(II) sulfate heptahydrate, for cell culture, 99% also has anti-tumor effects on chronic myeloid leukemia and breast cancer .

Iron(II) sulfate heptahydrate, for cell culture, 99%

1 Publications Verification

Ferrous sulfate heptahydrate, for cell culture, 99%

Biochemical Assay Reagents

Iron(II) sulfate heptahydrate, for cell culture, 99% (Ferrous sulfate heptahydrate, for cell culture, 99%) is an orally active iron salt. Iron(II) sulfate heptahydrate, for cell culture, 99% replaces iron found in hemoglobin and myoglobin, allowing for the transportation of oxygen via hemoglobin. Iron(II) sulfate heptahydrate, for cell culture, 99% is mainly used for the prevention of iron-deficiency anemia. Iron(II) sulfate heptahydrate, for cell culture, 99% also has anti-tumor effects on chronic myeloid leukemia and breast cancer .

HY-47030

Ferric citrate hydrate	Biochemical Assay Reagents
Ferric citrate hydrate, an orally active iron supplement, is an efficacious phosphate binder. Ferric citrate hydrate can be used for iron deficiency anemia and chronic kidney disease (CKD) research .

Cat. No.	Product Name	Target	Research Area

HY-P3761

Ac-Tyr-Val-Lys-Asp-aldehyde	Caspase	Inflammation/Immunology
Ac-Tyr-Val-Lys-Asp-aldehyde is a reversible caspase-1 inhibitor. Ac-Tyr-Val-Lys-Asp-aldehyde increases GATA1 levels by inhibiting caspase-1 and promotes erythroid differentiation. can be used for disease research including anemia-associated to chronic diseases, chemotherapy-induced anemia and Diamond-Blackfan anemia .

HY-P5908

DEALA-Hyp-YIPD	Peptides	Cardiovascular Disease
DEALA-Hyp-YIPD is an HIF-1α peptide that inhibits VHL/HIF-1α interaction with an IC₅₀ of 0.91 μM and a K_d of 180 nM .

Cat. No.	Product Name	Target	Research Area	Image

HY-P990965

Efparepoetin alfa	Inhibitory Antibodies	Inflammation/Immunology
Efparepoetin alfa is an EPO receptor agonist. Efparepoetin alfa can be used in the research of anemia caused by chronic kidney disease .

HY-P991881

KY1070	TGF-β Receptor Hepcidin Ferroportin	Cardiovascular Disease
KY1070 is a fully human anti-BMP6 antibody with a K_d of 0.00014 μM against the human BMP6. It exhibits high specificity for BMP6, showing no cross-reactivity with other members of the BMP family, and effectively inhibits BMP6-induced BMP receptor heterodimerization and hepcidin expression. KY1070 modulates Ferroportin expression on erythroid progenitor cells and accelerates erythropoiesis. In rodent anemia models, KY1070 reduces the required dose of erythropoietin (EPO) when used in combination with EPO and enhances the responsiveness of mice with chronic kidney disease (CKD)-associated anemia to EPO treatment. KY1070 is applicable for research on anemia of chronic disease ^{[1] [2]}.

Cat. No.	Product Name	Chemical Structure

HY-101277S1

Vadadustat-13C6
Vadadustat- ¹³C₆ (PG-1016548- ¹³C₆) is ¹³C labeled Vadadustat. Vadadustat (PG-1016548) is a titratable, oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor . Vadadustat is an erythropoiesis-stimulating agent and has the potential for anemia treatment in chronic kidney disease in vivo .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.